Acorda Therapeutics Inc. | Ownership
Companies that own Acorda Therapeutics Inc.
Scopia Capital Management LP
7,106,955
14.97%
-529,611
3.51%
09/06/2018
BlackRock Fund Advisors
6,482,253
13.65%
366,159
0.01%
06/30/2018
Fidelity Management & Research Co.
6,077,586
12.8%
-43,029
0.02%
06/30/2018
The Vanguard Group, Inc.
4,786,531
10.08%
453,257
0%
06/30/2018
Dimensional Fund Advisors LP
2,965,704
6.25%
-156,071
0.02%
06/30/2018
Partner Fund Management LP
2,188,368
4.61%
-1,213,153
1.09%
06/30/2018
SSgA Funds Management, Inc.
1,864,294
3.93%
-636,000
0%
06/30/2018
Invesco Capital Management LLC
1,301,519
2.74%
1,062,147
0.02%
06/30/2018
Northern Trust Investments, Inc.
1,052,739
2.22%
10,616
0.01%
06/30/2018
Norges Bank Investment Management
967,797
2.04%
535,434
0%
12/31/2017
| Address |
420 Saw Mill River Road
Ardsley New York 10502
United States
|
|
Employees
|
- |
| Website |
http://www.acorda.com |
| Updated |
07/08/2019 |
| Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its two main products are Ampyra and Zanaflex Capsules. The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis and Zanaflex Capsules, which is a short acting drug for the management of spasticity, a symptom of many central nervous system disorders, including multiple sclerosis and spinal cord injury. |
